Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana

详细信息    查看全文

• 作者：Jorge A. Gó ; mez ; PhD ; MCE¹ ; ^{Jorge.A.Gomez@gsk.com} ; Alberto Villaseñ ; or-Sierra ; MD² ; Gerardo Martí ; nez Aguilar ; MD³ ; Roberto Carreñ ; o Manjarrez ; MD⁴ ; Marí ; a Y. Cervantes-Apolinar ; MD⁴
• 关键词：Cost effectiveness ; Streptococcus pneumoniae ; prevention of pneumococcal disease ; pediatric population ; Mexico
• 刊名：Value in Health Regional Issues
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：Complete
• 页码：76-84
• 全文大小：655 K
• 卷排序：11

文摘

To estimate the cost effectiveness associated with the use of pneumococcal conjugated vaccines, Prevenar-13 and Synflorix®, in the Mexican pediatric population.MethodsThe cost-effectiveness ratio of instrumenting vaccination programs based upon the use of Prevenar-13 and Synflorix® in the Mexican pediatric population was estimated by using a Markov’s simulation model. The robustness of the conclusions reached on cost-effectiveness for both vaccines was assayed through an univariate and probabilistic sensitivity analysis that included all of the parameters considered by the model.ResultsSynflorix® was dominant over Prevenar-13 in the cost-utility analysis; the former generated more quality-adjusted life years at a lower cost and with a lower incremental cost-utility ratio. Based on the cost-effective analysis, Prevenar-13 generated more life years gained but at a higher cost. The use of Prevenar-13 originated a higher incremental cost-effectiveness ratio and, therefore, it was not cost-effective as compared with Synflorix®.ConclusionsEven though the simulations for Prevenar-13 and Synflorix® revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix® had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix® produced equivalent health outcomes, the overall analysis predicted that Synflorix® would save 360 million Mexican pesos, as compared with Prevenar-13.